Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting ...

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating ...

The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.